Underwriting

Slides from Hank's presentation at the WAHLU 2019 Spring Seminar have been posted at the WAHLU website.

The cutting edge of the insurance industry involves adjusting premiums and policies based on new forms of surveillance.

The impact of genetic testing on the insurance industry will continue to be an important topic of actuarial research for some time as insurers address its effect on pricing and valuation. Insurance product development opportunities may also emerge to capitalize upon the genetics revolution. This paper explores the implications for the insurance industry.

Blood taken from insurance examinations are subject to many possible influences. Delays in handling, processing, and different atmospheric conditions may causes changes to lab results as opposed to those you would avoid when the labs are processed locally.

The risks associated with the practice of mixed martial arts (MMA) should always be assessed with a high level of attention. The practice of this sport, however, does not yet say everything about the risk potential.

Indirect use of discrimination factors that are outlawed is inexcusable and needs to be avoided by due diligence by insurer and indeed the firm supplying the data. Any decent carrier would not want to cross those red lines anyway – and that is even if the data company involved is not itself subject to regulatory oversight and/or consumer protection laws. Moral: act with integrity and choose your business partners carefully.

Slides for the presentation at ReFocus 2019, March 10-13, Las Vegas

In this age of amazing medical advances, it seems as though anything broken can be fixed.  In my native South Africa, the surgeon Dr. Christiaan Barnard proved that even defective hearts can be replaced when he performed the first heart transplant in 1967.

Rapid medical advances, as well as growing volumes of health and mortality data, are transforming cancer risk assessment. RGA's Neil Parkin explores our deepening understanding and insurance implications.